74 related articles for article (PubMed ID: 19133777)
1. Effect of fluorination on the pharmacological profile of 11beta isomers of fulvestrant in breast carcinoma cells.
Agouridas V; Magnier E; Blazejewski JC; Laïos I; Cleeren A; Nonclercq D; Laurent G; Leclercq G
J Med Chem; 2009 Feb; 52(3):883-7. PubMed ID: 19133777
[TBL] [Abstract][Full Text] [Related]
2. Nonpolar and short side chain groups at C-11beta of estradiol result in antiestrogens.
Zhang JX; Labaree DC; Hochberg RB
J Med Chem; 2005 Mar; 48(5):1428-47. PubMed ID: 15743187
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
Mendoza-Sanchez R; Cotnoir-White D; Kulpa J; Jutras I; Pottel J; Moitessier N; Mader S; Gleason JL
Bioorg Med Chem; 2015 Dec; 23(24):7597-606. PubMed ID: 26613635
[TBL] [Abstract][Full Text] [Related]
4. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
5. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
Treeck O; Haldar C; Ortmann O
Oncol Rep; 2006 Jan; 15(1):231-5. PubMed ID: 16328061
[TBL] [Abstract][Full Text] [Related]
6. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues.
Saha P; Descôteaux C; Brasseur K; Fortin S; Leblanc V; Parent S; Asselin E; Bérubé G
Eur J Med Chem; 2012 Feb; 48():385-90. PubMed ID: 22209414
[TBL] [Abstract][Full Text] [Related]
8. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators.
Wittmann BM; Sherk A; McDonnell DP
Cancer Res; 2007 Oct; 67(19):9549-60. PubMed ID: 17909066
[TBL] [Abstract][Full Text] [Related]
9. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
10. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.
Fan M; Yan PS; Hartman-Frey C; Chen L; Paik H; Oyer SL; Salisbury JD; Cheng AS; Li L; Abbosh PH; Huang TH; Nephew KP
Cancer Res; 2006 Dec; 66(24):11954-66. PubMed ID: 17178894
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells.
Perron V; Rabouin D; Asselin E; Parent S; C-Gaudreault R; Bérubé G
Bioorg Chem; 2005 Feb; 33(1):1-15. PubMed ID: 15668178
[TBL] [Abstract][Full Text] [Related]
14. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
15. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
[TBL] [Abstract][Full Text] [Related]
18. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.
Michalides R; Griekspoor A; Balkenende A; Verwoerd D; Janssen L; Jalink K; Floore A; Velds A; van't Veer L; Neefjes J
Cancer Cell; 2004 Jun; 5(6):597-605. PubMed ID: 15193262
[TBL] [Abstract][Full Text] [Related]
20. The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells.
Tong GM; Rajah TT; Zang XP; Pento JT
Anticancer Res; 2002; 22(1A):103-6. PubMed ID: 12017270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
